• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Ionis Pharmaceuticals (IONS) Is Up 6.2% After New Cardiometabolic Data Spotlight TRYNGOLZA And ION775

    Simply Wall St·08/28/2026 13:24:04
    Listen to the news
    • Ionis Pharmaceuticals announced that, at the European Society of Cardiology Congress 2026, it presented one-year data for newly approved TRYNGOLZA in severe hypertriglyceridemia alongside early-stage results for next-generation candidate ION775 and detailed Phase 3 data for eplontersen in transthyretin-mediated amyloid cardiomyopathy.
    • These datasets spotlight Ionis’s push to expand TRYNGOLZA from rare familial chylomicronemia syndrome into broader severe hypertriglyceridemia care while advancing RNA-based cardiometabolic and amyloidosis therapies that could reshape how high-risk patients are managed.
    • We’ll now examine how the new long-term TRYNGOLZA data and next-generation ION775 profile could influence Ionis’s severe hypertriglyceridemia investment narrative.

    This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.

    Ionis Pharmaceuticals Investment Narrative Recap

    To own Ionis today, you need to believe its RNA platform can convert TRYNGOLZA’s early traction in familial chylomicronemia syndrome into a broader severe hypertriglyceridemia franchise, while late stage assets gradually narrow current losses. The ESC 2026 data on one year TRYNGOLZA use and ION775’s early profile matter mainly because near term sentiment hinges on the sHTG launch ramp, while the biggest risk remains pricing pressure and label or reimbursement outcomes that cap margins as volumes rise.

    Among recent announcements, the June 2026 U.S. approval of TRYNGOLZA for severe hypertriglyceridemia is the clearest reference point for this ESC update. The new one year extension data and early ION775 results will likely be read directly against that approval as investors reassess how durable TRYNGOLZA looks in real world style use and how quickly Ionis might migrate patients to longer acting follow ons, both of which tie back into the core revenue growth and pricing risk debate.

    Yet for all the excitement around TRYNGOLZA’s broader reach, investors should also be aware that pricing pressure across both FCS and sHTG could...

    Read the full narrative on Ionis Pharmaceuticals (it's free!)

    Ionis Pharmaceuticals’ narrative projects $2.3 billion revenue and $222.2 million earnings by 2029.

    Uncover how Ionis Pharmaceuticals' forecasts yield a $88.00 fair value, a 41% upside to its current price.

    Exploring Other Perspectives

    IONS 1-Year Stock Price Chart
    IONS 1-Year Stock Price Chart

    Before this ESC news, the most optimistic analysts were modeling revenue to reach about US$2.9 billion and earnings near US$708 million by 2029, assuming TRYNGOLZA’s sHTG launch and other late stage programs dramatically outperformed consensus. That is a much more bullish story than the baseline, which already flags pricing and regulatory setbacks as key risks. As you weigh today’s new sHTG data and ION775 signals, remember that these pre news forecasts may need to be revisited in light of how the launch and pricing picture actually evolves.

    Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth just $79.71!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    • A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards that could impact your investment decision.
    • Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

    No Opportunity In Ionis Pharmaceuticals?

    The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.